Prostate Cancer: A PSA on PSA

Key Takeaways

• Advanced-stage prostate cancer diagnoses rising in US and Canada
• PSA velocity and density improve early detection while reducing false alarms
• Contrast-free biparametric MRI halves scan time, maintains diagnostic accuracy
• Transperineal biopsy eliminates infection risk, improves high-grade cancer detection

Pulse Analysis

The recent surge in metastatic prostate cancer cases has reignited debate over the value of population‑wide PSA screening. Epidemiologists attribute the rise to the 2008 and 2012 USPSTF recommendations that discouraged routine testing, especially for men over 70. While overall incidence remains stable, the proportion of cancers caught at stage III or IV has climbed sharply, eroding the 44‑64% mortality reductions documented in long‑term trials. This shift underscores a critical public‑health blind spot: without systematic early‑detection, even the most advanced therapies cannot reverse the poor prognosis of late‑stage disease.

Advances in biomarker analytics now allow clinicians to extract far more information from a simple blood draw. By establishing a patient’s baseline PSA and monitoring its velocity—how quickly the level rises year over year—physicians can differentiate benign age‑related increases from malignant trends. Adding PSA density, calculated from prostate volume measured on MRI, further refines risk stratification. The 2025 PRIME trial demonstrated that a contrast‑free biparametric MRI delivers diagnostic performance on par with full multiparametric protocols while cutting scan time in half, making high‑resolution imaging accessible to broader populations. Together, these tools create a layered screening pathway that catches aggressive tumors early without flooding the system with unnecessary biopsies.

Biopsy methodology has also evolved. The traditional transrectal approach carries a 5‑7% infection risk, whereas transperineal biopsy, now supported by large phase‑3 data, shows near‑zero infections and superior sampling of anterior prostate zones. When combined with active‑surveillance protocols for low‑grade disease, the modern workflow minimizes overtreatment while ensuring high‑grade cancers receive timely intervention. Policymakers and professional societies must reassess outdated screening guidelines in light of these technological gains, promoting routine, nuanced PSA testing paired with MRI and safer biopsy techniques to restore the mortality benefits once promised by early detection.